FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor
Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/7/2023 | $20.00 | Buy | Craig Hallum |
| 12/1/2022 | $25.00 | Outperform | Cowen |
| 10/21/2022 | $14.00 | Buy | Jefferies |
| 10/11/2022 | $11.00 | Mkt Perform → Outperform | SVB Leerink |
| 8/2/2022 | $10.00 | Buy | Maxim Group |
| 9/9/2021 | $6.00 | Market Perform | SVB Leerink |
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
Craig Hallum initiated coverage of scPharmaceuticals with a rating of Buy and set a new price target of $20.00
Cowen initiated coverage of scPharmaceuticals with a rating of Outperform and set a new price target of $25.00
Jefferies resumed coverage of scPharmaceuticals with a rating of Buy and set a new price target of $14.00
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an
10-Q - scPharmaceuticals Inc. (0001604950) (Filer)
8-K - scPharmaceuticals Inc. (0001604950) (Filer)
10-Q - scPharmaceuticals Inc. (0001604950) (Filer)
Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, November 13th, at 4:30pm ET BURLINGTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare th
BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it will host a KOL webinar focused on a nephrologist's perspective on the use of FUROSCIX for treating fluid overload in heart failure and potential use for patients with chronic kidney disease (CKD) on Tuesday, October 22, 2024 at 1:00 PM ET. To register, click here. https://lifescievents.com/event/scpharmaceuticals/ The event will feature Dr. Michael Aaronson, MD (Lincoln Nephrolog
BURLINGTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00AM ET. Mr. Tucker will also be meeting with investors that day. A webcast of the presentation can be accessed here or under "News & Events" in the Investor Relations section of the Company's website, www.scPharmaceuticals.
Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form
scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Supplemental New Drug Application (sNDA) seeking to expand the FUROSCIX indication to include treatment of edema due to fluid overload in patients with chronic kidney disease (CKD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025. In Type D meeting feedback provided by the FDA last year, the ag
HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price target.
scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.44) by 18.18 percent. The company reported quarterly sales of $6.10 million which beat the analyst consensus estimate of $5.98 million by 2.05 percent. This is a 195.69 percent increase over sales of $2.06 million the same period last year.
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, November 13th, at 4:30pm ET BURLINGTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare th
Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, sNDA submission for CKD, and positive topline pivotal PK data for our Autoinjector Company to host investor conference call and webcast today, Wednesday, August 14th, at 4:30pm ET BURLINGTON, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient car
BURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, August 14, 2024, to discuss the financial results for the second quarter 2024 and provide a business update. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13747259. To access the new Call me™ feature, which avoids hav
4/A - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)